bursting tumour

Read about thermal immuno-nanomedicine in our Feb 2023 issue

  • Zhe Yang
  • Di Gao
  • Xingcai Zhang
Review Article

Announcements

  • signalling pathways

    "Predicting tumour radiosensitivity to deliver precision radiotherapy" from James Price et al. will be freely available for one month after the publication date of our February 2023 issue

  • viral particles

    Read all the COVID-19-related contents published in our journal, which will be freely available during the pandemic

Advertisement

    • Data obtained using omics technologies can offer important insights into various aspects of chimeric antigen receptor (CAR) T cell therapy. In this Review, the authors provide an overview of the multidimensional profiling technologies that have been applied in investigations of CAR T cell therapy. They then discuss the ways in which multi-omics data obtained through such analyses can be used to elucidate CAR targets, factors associated with response or resistance to therapy, and mechanisms underlying the associated toxicities, which could potentially be exploited to improve the efficacy and safety of CAR T cell therapies.

      • Jingwen Yang
      • Yamei Chen
      • Leng Han
      Review Article
    • Caring for individuals with thyroid nodules requires accurate estimation of their risk of thyroid cancer; however, available diagnostic tools offer only imprecise estimates. Novel biomarkers might help to clarify thyroid cancer risk and facilitate more-accurate diagnostic decision-making, although limitations in this area continue to exist.

      • Naykky Singh Ospina
      • Juan P. Brito
      News & Views
    • Immune-checkpoint inhibitors (ICI) constitute a paradigm shift in the treatment of non-small-cell lung cancer (NSCLC); however, identifying the minority of patients who derive long-term benefit remains problematic, particularly among those with targetable oncogenic drivers who have typically been under-represented in or excluded from clinical trials of ICIs. This Review summarizes the associations of common oncogenic drivers of NSCLC with sensitivity or resistance to ICIs as well as the underlying effects on the immune tumour microenvironment. Potential vulnerabilities that could potentially be exploited to overcome primary resistance to ICIs conferred by certain oncogenic drivers are also highlighted.

      • Itziar Otano
      • Alvaro C. Ucero
      • Luis Paz-Ares
      Review Article
    • Preclinical models that faithfully recapitulate interactions between the human immune system and tumours are necessary to evaluate human-specific immunotherapies in vivo; however, their number is currently limited. The authors of this Review discuss the currently available humanized mouse models, which are immunodeficient mice co-engrafted with human tumours and immune components, with a focus on their applicability in translational research.

      • Jane Chuprin
      • Hannah Buettner
      • Michael A. Brehm
      Review Article
    • Oncolytic viruses (OVs) provide a novel cancer treatment strategy, with a mechanism of action and toxicity profiles that are distinctly different to those of more traditional therapies. Thus far, four OVs have entered clinical use globally, yet only talimogene laherparepvec (T-VEC) has entered widespread clinical use. In this Review, the authors describe the clinical and regulatory experience with T-VEC thus far, and how this can guide the development of novel OVs. Discussions of a range of novel OVs with the potential for clinical implementation in the near future are also provided.

      • Sophia Z. Shalhout
      • David M. Miller
      • Howard L. Kaufman
      Review Article

Nature Careers

Events

Jobs

Advertisement